Everest Medicines Partners with Corxel Pharmaceuticals to Advance Cardamyst Etripamil Nasal Spray in Greater China

Everest Medicines has entered into an asset purchase agreement with Corxel Pharmaceuticals to develop and commercialize Cardamyst (etripamil nasal spray) in Greater China. The deal strengthens Everest’s cardiovascular portfolio by securing rights to a novel, fast-acting nasal spray designed for the treatment of paroxysmal supraventricular tachycardia (PSVT).

Strategic Expansion in Cardiovascular Therapeutics

The agreement allows Everest Medicines to expand its presence in cardiovascular care, particularly in China, where the burden of cardiac rhythm disorders is rising. Cardamyst offers a non-invasive, self-administered treatment option, potentially improving patient convenience and reducing hospital visits. This aligns with Everest’s focus on innovative therapies addressing unmet medical needs in the region.

Strengthening Regional Commercialization Capabilities

By acquiring rights from Corxel Pharmaceuticals, Everest reinforces its strategy of in-licensing promising global assets for regional development. The partnership highlights growing collaboration between biotech firms to accelerate access to advanced therapies in Asia. It also positions Everest to leverage its local regulatory and commercialization expertise to bring Cardamyst to market efficiently.